Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant Strengthens Resolve To Build Vulnerable Plaque Market

This article was originally published in The Gray Sheet

Executive Summary

Guidant is backing its previously stated pledge to develop a market for the diagnosis and treatment of vulnerable plaque, investing in Miravant Medical Technologies' PhotoPoint photodynamic therapy
Advertisement

Related Content

Guidant, Boston Scientific Stocks Weather DES Issues
Guidant, Boston Scientific Stocks Weather DES Issues
Iridex/Miravant PDT For Macular Degeneration Granted FDA Expedited Review
Iridex/Miravant PDT For Macular Degeneration Granted FDA Expedited Review
DES For Vulnerable Plaque: Consensus Elusive With Current Imaging Tools
Advertisement
UsernamePublicRestriction

Register

MT020539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel